
Keywords: DXIFWWUDOXUTQH-UHFFFAOYSA-N; VXPBYVGXCVDFLZ-UHFFFAOYSA-N; KCOCTIZMUOBRME-UHFFFAOYSA-N; MQPLMBSDWYIIID-UHFFFAOYSA-N; KKUOWOQXXDOGDC-UHFFFAOYSA-N; BLBVOPKWOIXAFD-UHFFFAOYSA-NCelecoxib; Rofecoxib; COX-2 selectivity; Membrane permeabilization; Gastric adverse